Iovance Biotherapeutics, Inc. (2LB)
Summary
2LB Chart
Iovance Biotherapeutics: Commercial, Clinical And Regulatory Tailwinds
IOVA guides for $350M–$370M 2026 revenue (36% YoY growth), with Q2'26 expected to be a record Amtagvi quarter. Expansion into new indications (NSCLC, endometrial, sarcoma) and global markets underpins the pipeline-in-a-drug thesis. A more receptive FDA increases the likelihood of accelerated approvals based on single-arm data, streamlining IOVA's development path.
Iovance Biotherapeutics pushes cell therapy platform into solid tumor market
Iovance Biotherapeutics (NASDAQ:IOVA) said it has obtained clearance of an Investigational New Drug application for IOV-5001, extending its next-generation cell therapy platform into solid tumors the company said account for more than 100,000 US deaths a year. The clearance allows Iovance to begin clinical work on IOV-5001 and marks the platform's move beyond its current focus and into the solid tumor setting.
IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%
Iovance matches Q1 earnings estimates, but weaker-than-expected Amtagvi and Proleukin sales sent shares down 13% despite revenue growth.
Iovance Biotherapeutics, Inc. (2LB) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Iovance Biotherapeutics, Inc. ever had a stock split?
Iovance Biotherapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Frederick G. Vogt CEO | XMUN Exchange | US4622601007 ISIN |
| US Country | 838 Employees | - Last Dividend | 26 Sep 2013 Last Split | 15 Oct 2010 IPO Date |
Overview
Iovance Biotherapeutics, Inc. stands as a commercial-stage biotechnology entity dedicated to developing and commercializing innovative cell therapies. Utilizing autologous tumor infiltrating lymphocyte technology, the company aims to provide treatments for metastatic melanoma alongside other solid tumor cancers within the United States. Originating in 2007 and originally known as Lion Biotechnologies, Inc., the company transitioned to its current name in June 2017. With its headquarters in San Carlos, California, Iovance Biotherapeutics has established numerous strategic collaborations and licensing agreements with prominent institutions and companies across the healthcare and biotechnology sectors. These partnerships extend to WuXi Advanced Therapies, Inc.; National Institutes of Health; National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH, aiming to enhance its offering and impact in cancer treatment.
Products and Services
- Amtagvi
Described as a pioneering tumor-derived autologous T cell immunotherapy, Amtagvi is specifically designed for adult patients struggling with unresectable or metastatic melanoma. This product marks Iovance's commitment to offering advanced therapeutic options that leverage the body's immune system to fight cancer.
- Proleukin
An interleukin-2 product, Proleukin serves as a treatment solution for patients with metastatic renal cell carcinoma. Through boosting the patient's immune response, it aims at attacking and eliminating cancer cells, underscoring the company's expertise in immunotherapy.
- Lifileucel in combination with pembrolizumab
This development focuses on treating frontline advanced melanoma patients by combining lifileucel with pembrolizumab. The strategic integration of these treatments exemplifies Iovance's innovative approach towards providing comprehensive care for melanoma patients.
- LN-145
Targeted at addressing the challenges in non-small cell lung cancer (NSCLC) and other solid tumor cancers, LN-145 is an ongoing project that aims to expand the therapeutic reach of the company’s immunotherapy solutions.
- IOV-4001
Currently in Phase 1/2 IOV-GM1-201 clinical trial, IOV-4001 represents Iovance's commitment to innovating treatment options for NSCLC. This exploration into new therapies highlights the company’s dedication to contributing significant advancements in cancer treatment.
- Lifileucel for Gynecological Cancers
Another pivotal area of development, the application of lifileucel for treating gynecological cancers, signifies Iovance's broader endeavor to tackle a variety of cancer types with its cell therapy technologies.
